253 related articles for article (PubMed ID: 19295413)
1. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects.
Saketkoo LA; Espinoza LR
Am J Med Sci; 2009 May; 337(5):329-35. PubMed ID: 19295413
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.
Swigris JJ; Olson AL; Fischer A; Lynch DA; Cosgrove GP; Frankel SK; Meehan RT; Brown KK
Chest; 2006 Jul; 130(1):30-6. PubMed ID: 16840379
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
5. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
Yilmaz N; Can M; Kocakaya D; Karakurt S; Yavuz S
Int J Rheum Dis; 2014 Nov; 17(8):923-8. PubMed ID: 24864029
[TBL] [Abstract][Full Text] [Related]
6. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
[TBL] [Abstract][Full Text] [Related]
7. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis.
Mira-Avendano IC; Parambil JG; Yadav R; Arrossi V; Xu M; Chapman JT; Culver DA
Respir Med; 2013 Jun; 107(6):890-6. PubMed ID: 23517887
[TBL] [Abstract][Full Text] [Related]
8. Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease.
Kim GHJ; Tashkin DP; Lo P; Brown MS; Volkmann ER; Gjertson DW; Khanna D; Elashoff RM; Tseng CH; Roth MD; Goldin JG
Arthritis Rheumatol; 2020 Feb; 72(2):316-325. PubMed ID: 31430058
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.
Fischer A; Brown KK; Du Bois RM; Frankel SK; Cosgrove GP; Fernandez-Perez ER; Huie TJ; Krishnamoorthy M; Meehan RT; Olson AL; Solomon JJ; Swigris JJ
J Rheumatol; 2013 May; 40(5):640-6. PubMed ID: 23457378
[TBL] [Abstract][Full Text] [Related]
10. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.
Tashkin DP; Volkmann ER; Tseng CH; Roth MD; Khanna D; Furst DE; Clements PJ; Theodore A; Kafaja S; Kim GH; Goldin J; Ariolla E; Elashoff RM
Chest; 2017 Apr; 151(4):813-820. PubMed ID: 28012804
[TBL] [Abstract][Full Text] [Related]
11. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
12. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
13. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
[TBL] [Abstract][Full Text] [Related]
15. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.
Higuero Sevilla JP; Memon A; Hinchcliff M
Arthritis Res Ther; 2023 Jul; 25(1):118. PubMed ID: 37422652
[TBL] [Abstract][Full Text] [Related]
16. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.
Zamora AC; Wolters PJ; Collard HR; Connolly MK; Elicker BM; Webb WR; King TE; Golden JA
Respir Med; 2008 Jan; 102(1):150-5. PubMed ID: 17822892
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
Huapaya JA; Silhan L; Pinal-Fernandez I; Casal-Dominguez M; Johnson C; Albayda J; Paik JJ; Sanyal A; Mammen AL; Christopher-Stine L; Danoff SK
Chest; 2019 Nov; 156(5):896-906. PubMed ID: 31238042
[TBL] [Abstract][Full Text] [Related]
18. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study.
Takahashi K; Taniguchi H; Ando M; Sakamoto K; Kondoh Y; Watanabe N; Kimura T; Kataoka K; Suzuki A; Ito S; Hasegawa Y
BMC Pulm Med; 2016 Apr; 16(1):55. PubMed ID: 27094018
[TBL] [Abstract][Full Text] [Related]
19. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience.
Baqir M; Makol A; Osborn TG; Bartholmai BJ; Ryu JH
PLoS One; 2017; 12(5):e0177107. PubMed ID: 28542177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
